Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment
Authors:
- 4 June 2007
- journal article
- review article
- Published by Wiley in Internal Medicine Journal
- Vol. 37 (7) , 485-494
Abstract
Pulmonary arterial hypertension (PAH) is an important cause of mortality in systemic sclerosis (SSc). The symptoms are non‐specific and can be ascribed to other features of the disease, so it is often underrecognized until the late stages. Earlier treatment with new agents is associated with better treatment outcomes. The aim of this article is to develop evidence‐based guidelines for screening for PAH and interstitial lung disease (ILD) in SSc. PAH occurs in up to 27% of patients with SSc. Abnormal pulmonary function, particularly a disproportionate fall in carbon monoxide diffusing capacity (DLCO), can identify patients in the early stages of PAH, prompting further investigation in high‐risk patients (limited SSc of >10 years’ duration, symptoms and/or signs of PAH, DLCO 45 mmHg on echocardiography). Right heart catheter remains the diagnostic gold standard. An algorithm for screening with regular pulmonary function tests for the early detection of PAH and ILD in SSc is proposed.Keywords
This publication has 31 references indexed in Scilit:
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals of the Rheumatic Diseases, 2006
- Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung diseaseArthritis & Rheumatism, 2005
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- Isolated pulmonary hypertension in sclerodermaInternal Medicine Journal, 2005
- Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatmentInternal Medicine Journal, 2004
- A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonismAnnals of the Rheumatic Diseases, 2004
- Clinical classification of pulmonary hypertensionJACC, 2004
- TRACLEER® (bosentan), for the treatment of pulmonary arterial hypertension (PAH) - 6 month quality of life dataThe Journal of Heart and Lung Transplantation, 2004
- Predictors of end stage lung disease in systemic sclerosisAnnals of the Rheumatic Diseases, 2003
- Isolated diffusing capacity reduction in systemic sclerosisArthritis & Rheumatism, 1992